Makes no sense we were at 280 now we are at 130 what's changed. Affidx totally derisked and proved to be highly accurate at picking up all variants. On sale, first distributor can't keep up with demand
Ava6000 entered patient trials and at this point humans have been dosed with it.
Does it make sense we are a quid off the highs? Of course not...